Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Athanase Innovation AB is a forward-thinking investment company headquartered in Sweden. Its primary function is to identify and back operations focusing on technology-driven and innovative solutions, offering financial support and strategic oversight to growth companies in multiple sectors, including technology, healthcare, and sustainable energy. Athanase Innovation AB engages in dynamic capital allocation, aiming to facilitate the transformation of promising ideas into commercially successful enterprises. A notable feature of the company is its commitment to invest in ventures that promote technological advancement and foster long-term growth initiatives. In the financial markets, Athanase Innovation AB plays a significant role by bridging the gap between cutting-edge innovation and the resources needed to scale, underscoring the importance of venture capital in nurturing the next generation of industry leaders. This makes Athanase Innovation AB integral to seed-stage ventures aspiring to achieve meaningful impact through innovation.
kr 1.30
kr 0.24 (-15.58%)
EOD Jun 23, 2026 · Twelve Data
51.84% operating margin is above average. ROIC at 2.52%. Note that capital returns lag the margin, the business may be capital-intensive despite high margins.
Revenue growth slowed to 0.9%, essentially flat. This is a business that needs a catalyst.
Free cash flow declined 21% versus the prior year, cash generation momentum has weakened. Net debt of kr 383M represents 17.1x FCF, leverage limits flexibility.
7.0x earnings, 1.9x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 42M
▲ +0.9% YoY
Net Income (TTM)
kr 6M
▼ -1.8% YoY
Op. Margin
51.84%
▼ -0.8pp YoY
ROIC
2.52%
Cash Flow & Balance Sheet
FCF (TTM)
kr 22M
▼ -21.3% YoY
Op. Cash Flow (TTM)
kr 22M
▼ -21.3% YoY
Net Debt
kr 383M
Cash & Equiv.
kr 15M
Continue Research
At a P/E of 7.0 and a price-to-free-cash-flow of 1.9, Athanase Innovation AB (ATIN.XSTO) trades below a two-stage DCF intrinsic value of about SEK 138.92 per share, so at SEK 1.30 the stock looks undervalued (10,586.5% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Athanase Innovation AB scores 62/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 52.2%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about SEK 138.92 per share for ATIN.XSTO, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around SEK 104.19. At today's SEK 1.30, that puts the stock about 10,586.5% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Athanase Innovation AB scores 62 out of 100 on Intrinsiqq's quality score, passing 4 of 8 checks, which makes it a solid business on these measures. Recent fundamentals include a 51.8% operating margin and a 2.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
Yes, Athanase Innovation AB pays a regular dividend of about SEK 7.52 per share per year (typically in quarterly installments), a yield of roughly 52.2% at the current price. That is a payout ratio of about 364.5% of earnings, so the dividend is stretched at this level. Athanase Innovation AB has grown the dividend at roughly 41.4% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For ATIN.XSTO's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. ATIN.XSTO currently trades below its estimated intrinsic value and scores 62/100 on quality (solid). It also yields about 52.2%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.